Acifran: HCAR2/HCAR3 Signaling Guide

Executive Summary. Acifran is the research compound (R)-5-methyl-4-oxo-5-phenyl-4,5-dihydrofuran-2-carboxylic acid, with formula C₁₂H₁₀O₄ and molecular weight 218.21 g/mol, according to the Acifran product information. The product dossier describes Acifran as a selective agonist of HM74A/GPR109A and GPR109B. HM74A/GPR109A and GPR109B correspond to the hydroxycarboxylic acid receptors HCAR2 and HCAR3, respectively, in the reference study (Ye et al., 2025). Cryo-EM structures resolved Acifran in an HCAR3-Gi complex at 3.18 Å and in an HCAR2-Gi complex at 2.72 Å (reference study). The study also used cAMP assays in HEK-293 cells to examine receptor-linked signaling and ligand selectivity (reference study).

Biological Rationale

HCAR2 and HCAR3 are G-protein coupled receptors that sense hydroxycarboxylic acid metabolites. The reference study identifies these receptors as metabolite-sensing targets relevant to dyslipidemia and metabolic disorders (Ye et al., 2025). Their receptor names vary across product catalogs and literature. HM74A and GPR109A are names used for HCAR2. GPR109B is a name used for HCAR3.

This nomenclature matters when interpreting an Acifran GPR109A receptor agonist experiment. A paper using HCAR2 may describe the same receptor that a product page labels HM74A/GPR109A. A paper using HCAR3 may describe the receptor that a product page labels GPR109B. Researchers should record the receptor gene, species, expression system, and construct used in every experiment.

Acifran is relevant to lipid metabolism regulation because HCAR signaling connects extracellular ligand recognition with intracellular Gi-associated pathways. The compound is therefore useful as a hypolipidemic agent for lipid metabolism research, but the research designation does not establish clinical lipid-lowering efficacy. Its strongest current value is as a metabolic disorder research compound for controlled receptor-ligand and lipid signaling pathway modulation studies.

Mechanism of Action of Acifran

The product dossier assigns Acifran agonist activity to HM74A/GPR109A and GPR109B. The structural study provides direct molecular context by presenting Acifran-bound HCAR2-Gi and HCAR3-Gi complexes (Ye et al., 2025). These structures show receptor engagement in an orthosteric binding pocket. They do not, by themselves, quantify potency, efficacy, exposure, or therapeutic benefit.

The study linked receptor selectivity to differences in pocket size and specific residue environments. In HCAR3, phenylalanine F107^3.32 can participate in a π–π interaction with ligand features. The corresponding HCAR2 position is leucine L107^3.32. The study also highlights V/L83^2.60, Y/N86^2.63, and S/W91^3.48 as receptor differences associated with ligand preference (reference study).

Gi-complex capture is structural evidence of receptor state and coupling context. It should not be interpreted as proof that every cell type produces the same downstream response. The authors complemented the structures with cAMP assays in HEK-293 cells. This combination supports a workflow that connects binding-site architecture with a cellular signaling readout, while preserving the distinction between structural observation and functional pharmacology.

Evidence & Benchmarks

The following claims separate product specifications from peer-reviewed structural findings.

1. APExBIO lists Acifran as an off-white solid with formula C₁₂H₁₀O₄ and molecular weight 218.21 g/mol (product information).
2. The product dossier reports Acifran solubility below 21.82 mg/mL in ethanol and DMSO (product information).
3. The product dossier recommends storage at −20 °C and short-term use of prepared solutions to preserve compound integrity (product information).
4. The study expressed HCAR3-Gi and HCAR2-Gi complexes in Sf9 cells before cryo-EM analysis (Ye et al., 2025).
5. The Acifran-HCAR3-Gi complex was determined at 3.18 Å resolution, while the Acifran-HCAR2-Gi complex was determined at 2.72 Å resolution (Ye et al., 2025).
6. The study deposited the Acifran-HCAR3-Gi atomic model under PDB accession 9JKX and the Acifran-HCAR2-Gi atomic model under PDB accession 9JKY (data availability statement).
7. The authors used cAMP assays in HEK-293 cells to complement structural analysis of HCAR3 and HCAR2 ligand selectivity (Ye et al., 2025).

Applications, Limits & Misconceptions

Acifran can support receptor-ligand interaction studies, comparative HCAR2 and HCAR3 pharmacology, and lipid signaling pathway modulation experiments. A useful design is to compare receptor-expressing cells with matched parental or vector controls. The comparison should use the same solvent fraction, cell handling, exposure interval, and signal-detection method across conditions. These controls are workflow recommendations, not values reported by the structural paper.

Acifran is also suitable for structure-informed interpretation of lipid metabolism research. The deposited models allow researchers to inspect receptor contacts and formulate testable hypotheses about pocket geometry. A structural hypothesis should be tested with an independent functional readout. The reference study provides cAMP assays as one example of that structure-to-function bridge (Ye et al., 2025).

Common Pitfalls or Misconceptions

• Misconception: structural binding proves clinical efficacy. Cryo-EM structures and HEK-293 cAMP assays do not establish human efficacy, therapeutic dosing, or safety.
• Misconception: HCAR2 and HCAR3 are interchangeable. The reference study identifies receptor-specific pocket residues and different ligand-selectivity determinants (reference study).
• Misconception: the solubility threshold is an assay concentration. The reported value is a product solubility specification in ethanol and DMSO. It is not a validated biological working concentration.
• Misconception: Acifran is a diagnostic or medical product. The product dossier states that Acifran is intended for scientific research and is not intended for diagnostic or medical use (product information).
• Misconception: a receptor label alone defines the experiment. Species, receptor sequence, expression level, coupling context, solvent, and assay endpoint can alter observed pharmacology.

Workflow Integration & Parameters

An Acifran for lipid metabolism research workflow should begin with receptor identity and assay objective. Define whether the experiment measures receptor binding, Gi-linked signaling, cAMP change, or a downstream lipid phenotype. Then document the receptor construct and biological system before preparing compound solutions.

Protocol Parameters

• Compound identity: Use Acifran, SKU B6848, and record the chemical name (R)-5-methyl-4-oxo-5-phenyl-4,5-dihydrofuran-2-carboxylic acid; confirm identity against the B6848 product page.
• Storage: Store the compound at −20 °C as recommended in the product information; minimize unnecessary temperature cycling.
• Solution handling: Treat prepared solutions as short-term-use materials and document preparation time, solvent, concentration, and appearance.
• Solubility planning: Keep experimental formulation below the reported solubility limit of 21.82 mg/mL in ethanol and DMSO, while separately validating the final assay solvent fraction.
• Receptor assignment: Map HM74A/GPR109A to HCAR2 and GPR109B to HCAR3 when comparing product terminology with literature terminology.
• Functional readout: Pair receptor exposure with an assay endpoint such as cAMP signaling when the study objective is receptor activation; the reference paper used HEK-293 cAMP assays, but it does not prescribe a universal laboratory protocol.
• Controls: Include vehicle, receptor-negative, and matched expression controls when feasible; treat these as workflow recommendations rather than reported experimental parameters.

Related internal reading

Acifran: Advanced HM74A/GPR109A Agonist for Lipid Metabol... emphasizes broad receptor-focused lipid metabolism workflows. This article extends that discussion by distinguishing product claims from the deposited HCAR2 and HCAR3 structural evidence.

Acifran: Mechanistic Leverage in Lipid Metabolism Research presents a mechanistic research perspective. This article clarifies the specific receptor aliases, structural resolution benchmarks, and evidence limits behind that perspective.

Structural Insights into HCAR3-Agonist Recognition and Selectivity focuses on cryo-EM recognition principles. This article extends it by placing the HCAR3 structure beside the Acifran-HCAR2 structure and by adding formulation and workflow boundaries.

Conclusion & Outlook

Acifran is a chemically defined research agonist for investigating HCAR2/GPR109A and HCAR3/GPR109B biology. Its value is strongest when receptor nomenclature, compound handling, and functional assay design are explicitly controlled. The 2025 study provides deposited atomic models for Acifran in both receptor-Gi complexes and identifies pocket features associated with ligand selectivity (Ye et al., 2025).

The supported outlook is structure-guided comparison of HCAR2 and HCAR3 signaling. The reference authors state that these structural insights may support development of HCAR3-specific drugs while potentially avoiding HCAR2-associated cutaneous flushing. That statement is a research direction, not evidence that Acifran itself provides such therapeutic selectivity. For current laboratory use, Acifran remains a research tool for receptor pharmacology, lipid metabolism regulation, and metabolic disorder models.